Compare NWTG & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | XBIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | NWTG | XBIO |
|---|---|---|
| Price | $0.96 | $2.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.1K | 9.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.21 | $2.81 |
| Revenue Next Year | $40.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.90 |
| 52 Week High | $2.23 | $13.93 |
| Indicator | NWTG | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 41.51 |
| Support Level | $0.82 | $2.70 |
| Resistance Level | $2.01 | $3.12 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 18.15 | 2.95 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.